DrugPatentWatch Database Preview
Amring Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for AMRING PHARMS, and what generic alternatives to AMRING PHARMS drugs are available?
AMRING PHARMS has eleven approved drugs.
There are eight US patents protecting AMRING PHARMS drugs.
There are eight patent family members on AMRING PHARMS drugs in two countries and nineteen supplementary protection certificates in nine countries.
Summary for Amring Pharms
| International Patents: | 8 |
| US Patents: | 8 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 11 |
Drugs and US Patents for Amring Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amring Pharms | MESALAMINE | mesalamine | SUPPOSITORY;RECTAL | 208362-001 | Jun 21, 2019 | AB | RX | No | No | Start Trial | Start Trial | ||||
| Amring Pharms | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | 8,487,005 | Start Trial | Y | Start Trial | ||
| Amring Pharms | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | 8,273,795 | Start Trial | Start Trial | |||
| Amring Pharms | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | 8,791,160 | Start Trial | Y | Start Trial | ||
| Amring Pharms | NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 210989-001 | Aug 22, 2018 | AP | RX | No | No | Start Trial | Start Trial | ||||
| Amring Pharms | BROMFENAC SODIUM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 202030-001 | Jan 9, 2013 | DISCN | No | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for AMRING PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 650 mg | ➤ Subscribe | 2011-05-24 |
International Patents for Amring Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006023001 | Start Trial |
| Japan | 2011168596 | Start Trial |
| Japan | 2008508275 | Start Trial |
| Japan | 5000504 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2006023000 | Start Trial |
| Japan | 5205053 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Amring Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1586316 | 11C0031 | France | Start Trial | PRODUCT NAME: BROMFENAC, SES SELS OU HYDRATES PHARMACOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
| 1586316 | 122011100019 | Germany | Start Trial | PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518 |
| 1429780 | SPC/GB12/058 | United Kingdom | Start Trial | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 1586316 | 2011C/027 | Belgium | Start Trial | PRODUCT NAME: BROMFENAC; AUTHORISATION NUMBER AND DATE: EU/1/11/692/001 20110523 |
| 0809498 | SPC/GB10/012 | United Kingdom | Start Trial | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 0364417 | 9690031-1 | Sweden | Start Trial | PRODUCT NAME: LATANOPROST |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
